Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tuberculosis.

Gary Maartens1, Robert J Wilkinson

  • 1Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town Medical School, Cape Town, South Africa. gary.maartens@uct.ac.za

Lancet (London, England)
|August 28, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of unnatural death following self-harm in South Africa: development and validation of multivariable prognostic models.

BMJ mental health·2026
Same author

A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis.

The New England journal of medicine·2026
Same author

Bedaquiline reloading strategies following interruptions during daily dosing.

Antimicrobial agents and chemotherapy·2026
Same author

Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blind phase 4 trial.

The Lancet. Respiratory medicine·2026
Same author

Determinants of drop-offs in the targeted universal tuberculosis testing care cascade among people with HIV in rural and urban facilities in South Africa.

Southern African journal of HIV medicine·2026
Same author

Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis.

Antimicrobial agents and chemotherapy·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Tuberculosis remains a major global health threat, particularly in low-income nations. Advances in diagnostics, treatment, and prevention offer hope, but require significant global effort and resources to implement effectively.

Area of Science:

  • Global Health
  • Infectious Diseases
  • Public Health Policy

Background:

  • Tuberculosis (TB) is a leading cause of mortality in low- and middle-income countries, exacerbated by HIV co-infection in sub-Saharan Africa.
  • Current diagnostic methods for TB are largely unchanged from a century ago, and the effectiveness of the BCG vaccine and latent TB treatment is limited in high-incidence areas.
  • The rise of multidrug-resistant (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) poses a significant challenge to global control efforts.

Purpose of the Study:

  • To review the current landscape of tuberculosis control, highlighting existing challenges and emerging solutions.
  • To emphasize the need for updated diagnostic, treatment, and preventive strategies.
  • To advocate for a coordinated global plan to combat tuberculosis.

Related Experiment Videos

Main Methods:

  • Review of existing literature on tuberculosis epidemiology, diagnostics, treatment, and prevention.
  • Analysis of the impact of HIV on TB incidence and control.
  • Discussion of the challenges posed by drug-resistant TB strains.

Main Results:

  • Multidrug treatment with directly observed therapy is cost-effective but hampered by treatment duration and drug resistance.
  • Emerging research is yielding new diagnostic, therapeutic, and preventive tools for TB.
  • Significant gaps remain in applying these advances to high-risk populations.

Conclusions:

  • Despite progress in research, the application of new TB interventions is hindered by logistical and resource challenges.
  • A comprehensive, coordinated global plan is essential for tuberculosis eradication.
  • Sustained political will and substantial resources are critical for success in the fight against tuberculosis.